Atrix Laboratories of Fort Collins, Colo., has begun a new roundof clinical studies of its two periodontal products, the PerioProduct and Atrisorb, the company said Tuesday.

The Perio Product is being re-evaluated in a clinical studydesigned to clarify some issues that arose from Phase IIIclinical trials completed earlier this year on patients withchronic periodontitis.

The company's first clinical studies of Atrisorb, its guidedtissue regeneration membrane, center on its efficacy in aidingthe reattachment of tissue after gum flap surgery.

Atrix's unique, proprietary drug delivery technology isbiodegradable.

(c) 1997 American Health Consultants. All rights reserved.